Category: peptide
Aliases: Imcivree
MC4R-selective melanocortin agonist — restores hypothalamic POMC pathway signaling in genetic obesity from POMC, PCSK1, LEPR, or BBS deficiency. FDA-approved for these specific monogenic obesities + Bardet-Biedl syndrome. Hyperpigmentation + erection (MC1R + MC4R cross) are class effects. PK (Imcivree label, 3 mg SC qd SS): Apparent V/F 75.2 L, effective t½ ~11 h, total apparent CL/F 7.15 L/h (typical 120 kg male, normal renal function). Free fraction ~0.2. SC bioavailability lower than IV due to interstitial protease/peptidase degradation + lymphatic clearance — F 0.85 estimated (label notes "lower than IV" without quoting; consistent with other small-peptide SC depots). Metabolized to small peptides by general catabolic pathways. First MC4R agonist approved for monogenic obesity (POMC/PCSK1/LEPR deficiency, BBS).
SC: 11h